| Nov 7 |
23andMe to Report Q2 FY2025 Financial Results
|
| Oct 31 |
23andMe turns to CFOs to fill director roles after mass board exit
|
| Oct 31 |
23andMe appoints three former CFOs as new directors—after the previous board all resigned
|
| Oct 30 |
23andMe regains compliance with Nasdaq listing requirements
|
| Oct 30 |
23andMe Regains Compliance With Nasdaq Listing Requirements
|
| Oct 29 |
23andMe Appoints Three New Independent Directors to Board
|
| Oct 28 |
Ancestry Says a 23AndMe Takeover Would Raise Antitrust Issues
|
| Oct 27 |
23andMe: Liquidity Pressures And Operational Instability Pose Significant Risks
|
| Oct 25 |
Ozempic and Alzheimer's, 23andMe's crisis, and Novo Nordisk wants a crackdown: Pharma news roundup
|
| Oct 24 |
The crisis at 23andMe, explained
|
